Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

Editorial summary Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. Unfortunately, very little is known regarding the mechanisms of resistance to such...

Full description

Bibliographic Details
Published in:	Genome Medicine
Main Authors:	Jake S. O’Donnell, Mark J. Smyth, Michele W. L. Teng
Format:	Article
Language:	English
Published:	BMC 2016-10-01
Subjects:	Immune Checkpoint Programme Death Ligand Effective Therapeutic Option Immunosuppressive Tumor Microenvironment Functional Exhaustion
Online Access:	http://link.springer.com/article/10.1186/s13073-016-0365-1

Similar Items

Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma
by: Tietze Stefanie, et al.
Published: (2021-04-01)

Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade
by: Cheng Xu, et al.
Published: (2023-04-01)

Up-Regulation of Immune Checkpoints in the Thymus of PRRSV-1-Infected Piglets in a Virulence-Dependent Fashion
by: Inés Ruedas-Torres, et al.
Published: (2021-05-01)

PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?
by: Asad Ullah, et al.
Published: (2022-08-01)

Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy
by: Vishnu Vijay Vijayan, et al.
Published: (2024-12-01)

The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review
by: Mutiara Indah Sari, et al.
Published: (2022-08-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
by: Ruby Dhar, et al.
Published: (2023-04-01)

Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape
by: Julio F. Inocencio, et al.
Published: (2024-09-01)

Immunotherapy: an emerging modality to checkmate brain metastasis
by: Aatiya Ahmad, et al.
Published: (2023-07-01)

Reversing NK cell exhaustion: a novel strategy combining immune checkpoint blockade with drug sensitivity enhancement in the treatment of hepatocellular carcinoma
by: Yuxiang Huang, et al.
Published: (2025-01-01)

Pheophorbide A–Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD–L1 Expression
by: Qinli Tong, et al.
Published: (2022-11-01)

Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies
by: Xiaodong Wang, et al.
Published: (2025-10-01)

Role of B cells in anti-PD-(L)1 therapy in tumor bearing mice
by: HOU Junlei, et al.
Published: (2024-04-01)

Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
by: Jhe-Cyuan Guo, et al.
Published: (2019-01-01)

Gut microbiome for predicting immune checkpoint blockade-associated adverse events
by: Muni Hu, et al.
Published: (2024-01-01)

Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?
by: Alexander Ciurej, et al.
Published: (2023-12-01)

Nanomaterials-based precision sonodynamic therapy enhancing immune checkpoint blockade: A promising strategy targeting solid tumor
by: Xinlun Dai, et al.
Published: (2023-12-01)

A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer
by: Mike Mason, et al.
Published: (2024-02-01)

Inhalable metal–organic framework-mediated cuproptosis combined with PD-L1 checkpoint blockade for lung metastasis synergistic immunotherapy
by: Chongzheng Yan, et al.
Published: (2024-05-01)

Regulatory T cells in immune checkpoint blockade antitumor therapy
by: An Zhang, et al.
Published: (2024-11-01)

Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
by: Isobel S. Okoye, et al.
Published: (2017-09-01)

Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity
by: Yanhong Liu, et al.
Published: (2025-03-01)

Decoding the immune microenvironment in osteosarcoma: new insights into checkpoints, vaccines, and CAR-T cells
by: Haitian Wang, et al.
Published: (2025-10-01)

Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?
by: Zhikun Guo, et al.
Published: (2024-03-01)

The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
by: Seung Bae Yoon, et al.
Published: (2024-03-01)

Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
by: Lara Heij, et al.
Published: (2023-03-01)

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
by: Keiichiro Suminaga, et al.
Published: (2025-02-01)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
by: Chao Cheng, et al.
Published: (2022-09-01)

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
by: Nan Zhang, et al.
Published: (2024-02-01)

CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
by: Nan Chen, et al.
Published: (2017-02-01)

Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment
by: Jun Zheng, et al.
Published: (2023-02-01)

Checkpoint inhibitor/interleukin‐based combination therapy of cancer
by: Keywan Mortezaee, et al.
Published: (2022-08-01)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
by: Jingjing Duan, et al.
Published: (2018-09-01)

The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation
by: Yalei Hu, et al.
Published: (2024-11-01)

Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies
by: Zhiwei Han, et al.
Published: (2025-03-01)

Impact of the tumor microenvironment on survival in anaplastic thyroid carcinoma
by: Chanchal Rana, et al.
Published: (2025-10-01)

Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
by: Valerio Nardone, et al.
Published: (2021-06-01)

LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy
by: M A A Mamun, et al.
Published: (2023-07-01)

Characteristics and clinical outcomes of checkpoint inhibitor-associated pneumonia in cancer patients: a retrospective analysis of 1 084 cases
by: YANG Yan, et al.
Published: (2024-08-01)

Engineering nanoliposomes to enhance cancer immunotherapy by reversing immunosuppression and synergistically boosting tumour immunogenicity
by: Chunmei Zhang, et al.
Published: (2023-09-01)